The MAVS gene (Mitochondrial Antiviral Signaling Protein) encodes a critical adaptor protein that serves as the central hub for Rig-I-like receptor (RLR) signaling in the innate immune response. Also known as VISA (Virus-Induced Signaling Adaptor), IPS-1 (IFN-β Promoter Stimulator Protein 1), and CARDIF (CARD Adaptor Inducing IFN-β), MAVS bridges viral RNA detection by cytosolic sensors to the activation of downstream signaling cascades that induce type I interferons and inflammatory cytokines [1].
Located on chromosome 20p13, MAVS is expressed ubiquitously with highest levels in liver, heart, and brain. In the central nervous system, MAVS is expressed in neurons, astrocytes, and microglia, where it plays crucial roles in antiviral defense and neuroinflammation. Recent research has revealed that MAVS dysregulation contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions through mechanisms involving chronic innate immune activation, mitochondrial dysfunction, and neuroinflammation [4][5][9].
| MAVS (Mitochondrial Antiviral Signaling Protein) | |
|---|---|
| Official Symbol | MAVS |
| Full Name | Mitochondrial Antiviral Signaling Protein |
| Other Names | VISA, IPS-1, CARDIF |
| Chromosomal Location | 20p13 |
| NCBI Gene ID | 57468 |
| OMIM | 609588 |
| Ensembl ID | ENSG00000088888 |
| UniProt ID | Q9Y2H9 |
| Expression | Ubiquitous (liver, heart, brain) |
The MAVS gene spans approximately 35 kb on chromosome 20 and consists of 10 coding exons. The gene produces multiple transcript variants through alternative splicing, with the major isoform encoding a protein of 540 amino acids. The promoter region contains NF-κB and IRF response elements, enabling inducible expression [1].
MAVS protein contains several functional domains that enable its signaling functions:
The transmembrane domain is essential for MAVS function, as it localizes the protein to mitochondria where it can interact with viral sensors and downstream signaling molecules. Mutations in this domain can disrupt signaling and increase susceptibility to viral infections [1][3].
MAVS serves as the central adaptor for RLR signaling:
Upstream Activation:
Downstream Signal Transduction:
Signal Amplification:
MAVS exploits unique mitochondrial properties for signaling:
Spatial Organization: Mitochondrial membrane provides organized platform for signal assembly
Metabolic Integration: MAVS signaling is influenced by mitochondrial metabolic state
Quality Control: Mitophagy pathways regulate MAVS turnover [6]
In the central nervous system, MAVS-mediated signaling provides antiviral protection:
Neuronal Defense: Neurons express MAVS and can mount interferon responses to viral infection [14]
Microglial Activation: MAVS in microglia detects viral RNA and triggers cytokine production
Astrocyte Responses: Astrocyte MAVS contributes to neuroinflammatory responses [18]
MAVS plays a complex role in AD pathogenesis:
Type I Interferon Signature: AD brains exhibit elevated type I interferon-stimulated genes (ISGs), indicating chronic activation of the MAVS pathway. This interferon signature correlates with disease severity and is thought to contribute to synaptic dysfunction and cognitive decline [4][15].
Amyloid-Beta Interaction: Amyloid-beta oligomers can activate RIG-I-MAVS signaling in microglia and neurons. Aβ binding to RIG-I triggers MAVS aggregation and downstream inflammatory responses, creating a vicious cycle of amyloid deposition and neuroinflammation [11].
MAVS-Dependent Neurotoxicity: Chronic MAVS activation in neurons leads to:
Cross-talk with cGAS-STING: MAVS signaling intersects with the cGAS-STING pathway for cytosolic DNA sensing, creating a broader innate immune activation state in AD brains [10].
MAVS contributes to PD pathogenesis through several mechanisms:
Alpha-Synuclein Interaction: Alpha-synuclein aggregates can activate RIG-I-MAVS pathway in microglia. Recent studies show that α-syn fibrils bind to RIG-I and trigger MAVS-dependent cytokine production, linking protein aggregation to innate immune activation [12].
Dopaminergic Neuron Vulnerability: MAVS is expressed in dopaminergic neurons of the substantia nigra. Viral infection or mitochondrial stress can activate MAVS, leading to interferon responses that promote neuronal death [5].
Neuroinflammation: MAVS-mediated chronic inflammation in PD:
Mitochondrial Dysfunction: MAVS and mitophagy pathways are interconnected. Mutations in PD genes like PINK1 and parkin affect MAVS-mediated signaling, creating a feed-forward loop between mitochondrial dysfunction and neuroinflammation [6][16].
MAVS dysregulation in ALS:
While primarily an autoimmune demyelinating disease, MS involves:
MAVS interacts with numerous proteins:
Upstream Sensors:
Downstream Signaling:
Adaptor Proteins:
Mitochondrial Proteins:
MAVS integrates with multiple pathways:
| Variant | Disease | Effect | Evidence |
|---|---|---|---|
| rs1131559 | AD | Risk allele | GWAS [4] |
| rs3747518 | PD | Altered function | Case-control [5] |
| Various | MS | Risk alleles | GWAS |
Alzheimer's Disease:
Parkinson's Disease:
Aging:
MAVS is expressed in all major brain cell types:
Neurons: High expression in cortical and hippocampal neurons. Neuronal MAVS responds to viral infection and can trigger cell-autonomous antiviral responses [14].
Astrocytes: Moderate expression in astrocytes. Astrocyte MAVS contributes to neuroinflammatory cytokine production and can respond to neuronal damage signals [18].
Microglia: High expression in microglia. Microglial MAVS is the primary sensor for viral RNA and a major source of MAVS-dependent neuroinflammation [12].
Targeting MAVS signaling offers potential for neurodegenerative disease treatment:
Anti-inflammatory Approaches:
Immunomodulation:
Mitochondrial Protection:
MAVAS as a biomarker:
MAVS connects to multiple key pathways: